Beta Drugs' oncology boom, margin jump fuel 30% rally

Market pulse

From the investor's mind

Dixon Technologies has shown remarkable growth, with revenue expanding from ₹4,400 crore in FY20 to ₹50,000 crore in FY26, and profit after tax (PAT) increasing from ₹120 crore to ₹1,600 crore over the same period. This signifies a substantial scale-up, as Aditya Kondawar highlighted that Dixon's entire FY20 PAT was achieved every 27 days in FY26. The company is reportedly eyeing an ambitious ₹1 lakh crore revenue target in a few years, a projection previously noted by Kotak Insti.

Word in the street

Beta Drugs Limited

Talk on the street this week centered on Beta Drugs, which has climbed nearly 30 percent over the last year. Investors pointed to a strong first quarter performance after a subdued period, with several growth drivers showing momentum. Gross margins expanded to 56.6 percent from 50.4 percent a year ago. The branded oncology segment grew 47 percent year over year to ₹33 crore, while the contract manufacturing business expanded by 41 percent. Some see its acquisition of Nivian as a promising entry into the IVF industry. Other discussions focused on the high barriers to entry in cancer drug manufacturing, noting only a small fraction of Indian CMOs have chemotherapy capabilities.

Yesterday's big moves

“It is not whether you are right or wrong that is important, but how much money you make when you are right and how much you lose when you are wrong.”

George Soros